Fig. 3.
Fig. 3. Incidence of EBV-LPD and EBV-LPD mortality as compared to historical controls. / (A) Incidence of EBV-LPD. Cumulative incidence of EBV-LPD in historical control patients (n = 26) with EBV-DNA more than or equal to 1000 geq/mL versus the incidence of EBV-LPD in the prospectively followed group after EBV-DNA more than or equal to 1000 geq/mL (n = 17) (P = .13). (B) EBV-LPD mortality. Cumulative incidence of EBV-LPD mortality in historical control patients (n = 26) with EBV-DNA more than or equal to 1000 geq/mL versus the incidence of EBV-LPD mortality in patients (n = 17) prospectively studied (P = .04). N indicates numbers of patients studied; O, observations (endpoints) done in the study group.

Incidence of EBV-LPD and EBV-LPD mortality as compared to historical controls.

(A) Incidence of EBV-LPD. Cumulative incidence of EBV-LPD in historical control patients (n = 26) with EBV-DNA more than or equal to 1000 geq/mL versus the incidence of EBV-LPD in the prospectively followed group after EBV-DNA more than or equal to 1000 geq/mL (n = 17) (P = .13). (B) EBV-LPD mortality. Cumulative incidence of EBV-LPD mortality in historical control patients (n = 26) with EBV-DNA more than or equal to 1000 geq/mL versus the incidence of EBV-LPD mortality in patients (n = 17) prospectively studied (P = .04). N indicates numbers of patients studied; O, observations (endpoints) done in the study group.

Close Modal

or Create an Account

Close Modal
Close Modal